TD Cowen Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $115

Benzinga · 23h ago
TD Cowen analyst Nicholas Lorusso maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $100 to $115.